Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma

Inclusion Criteria: * Histologically confirmed glioblastoma multiforme (GBM) and are at first or second relapse. * Hemoglobin ≥ 9.0 g/dl, absolute neutrophil count (ANC) ≥ 1,000 cells/µl, platelets ≥ 125,000 cells/µl * No active infection of HIV, HTLV and Syphilis * Adequate renal function * Adequate hepatic function * Adequate cardiac function * Adequate venous access for apheresis, and no other contraindications for leukapheresis * Voluntary informed consent is given. Exclusion Criteria: * Pregnant or lactating women. * Uncontrolled active infection. * History of hepatitis B or hepatitis C infection. * Previously treatment with any gene therapy products or cell therapy product in past 28 days. * Cannot undergo MRI with contrast or SPECT/CT * HIV infection. * Have autoimmune disorders * Have active infection or inflammatory disorders * Prescreening test results in expansion rate less than 5 folds * An allergy to gentamycin and/or streptomycin